ArticleAnnals of hematology2025
Microvesicles secreted by CoCl
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Innovative strategies for immune thrombocytopenia treatment: immunomodulatory mechanisms and clinical potential of mesenchymal stem cells.Stem cell research & therapy · 2026Review
- The anti-inflammatory effects of mesenchymal stem cells and their research progress in hematopoietic stem cell transplantation: A comprehensive review.Cell transplantationReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid hematopoietic regeneration post-hematopoietic stem cell transplantation (HSCT) is vital for prompt immune recovery, infection prevention, and averting complications such as anemia and thrombocytopenia. The hematopoietic stem cells (HSCs) produce mature blood cells through a process known as hematopoiesis that is tightly regulated by the hypoxic bone marrow microenvironment. However, the limited number of HSCs present in the bone marrow is one of the major challenges for successful HSCT. Hence, developing novel ex vivo expansion strategies that address the clinical limitations of the current HSCT becomes imperative. Our prior work demonstrated that priming of mesenchymal stromal cells (MSCs) with a hypoxia-mimetic compound, cobalt chloride (CoCl
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.